Grifols (NASDAQ:GRFS) PT Lowered to €16.00

Grifols (NASDAQ:GRFS – Get Rating) had its price objective trimmed by Deutsche Bank Aktiengesellschaft from €17.00 ($17.53) to €16.00 ($16.49) in a report issued on Tuesday, The Fly reports. The firm currently has a hold rating on the biotechnology company’s stock.

A number of other research analysts also recently issued reports on GRFS. Jefferies Financial Group started coverage on Grifols in a research note on Monday, July 25th. They issued a hold rating for the company. Morgan Stanley started coverage on Grifols in a research note on Friday, April 8th. They issued an equal weight rating for the company. Finally, Berenberg Bank upped their price objective on Grifols from €20.15 ($20.77) to €20.30 ($20.93) and gave the company a buy rating in a research note on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Grifols has an average rating of Hold and a consensus price target of $15.77.

Grifols Trading Down 2.1 %

Shares of Grifols stock opened at $8.90 on Tuesday. The company has a market capitalization of $6.12 billion, a P/E ratio of 7.81 and a beta of 0.28. The company has a current ratio of 2.68, a quick ratio of 0.91 and a debt-to-equity ratio of 1.20. The stock has a fifty day simple moving average of $11.19 and a 200 day simple moving average of $11.45. Grifols has a 12-month low of $8.28 and a 12-month high of $15.90.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Capital World Investors lifted its position in shares of Grifols by 15.2% during the 1st quarter. Capital World Investors now owns 17,172,143 shares of the biotechnology company’s stock valued at $200,571,000 after buying an additional 2,265,005 shares during the last quarter. Black Creek Investment Management Inc. lifted its holdings in Grifols by 17.7% during the 1st quarter. Black Creek Investment Management Inc. now owns 7,089,872 shares of the biotechnology company’s stock worth $82,810,000 after purchasing an additional 1,064,065 shares in the last quarter. Brandes Investment Partners LP lifted its holdings in Grifols by 21.9% during the 1st quarter. Brandes Investment Partners LP now owns 4,857,661 shares of the biotechnology company’s stock worth $56,737,000 after purchasing an additional 871,999 shares in the last quarter. First Trust Advisors LP lifted its holdings in Grifols by 6.0% during the 4th quarter. First Trust Advisors LP now owns 4,141,459 shares of the biotechnology company’s stock worth $46,509,000 after purchasing an additional 235,120 shares in the last quarter. Finally, State Street Corp lifted its holdings in Grifols by 1.0% during the 1st quarter. State Street Corp now owns 3,273,686 shares of the biotechnology company’s stock worth $38,238,000 after purchasing an additional 32,956 shares in the last quarter. Hedge funds and other institutional investors own 14.71% of the company’s stock.

About Grifols

(Get Rating)

Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.